---
title: "Rubicon Research Ltd (RUBICON) — Share Price, Financials & Analysis"
symbol: "RUBICON"
company: "Rubicon Research Ltd"
canonical: "https://tapetide.com/stocks/RUBICON"
isin: "INE506V01022"
nse_symbol: "RUBICON"
bse_code: "544578"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 29264.48
generated_at: "2026-09-13T18:26:33.048Z"
---

# Rubicon Research Ltd (RUBICON)

Canonical page: https://tapetide.com/stocks/RUBICON

## Company

- **NSE Symbol:** RUBICON
- **BSE Code:** 544578
- **ISIN:** INE506V01022
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2025-10-16
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** rubicon.co.in

## About

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, & commercialization of differentiated formulations.[1]

## Latest Price

- **Price:** ₹1835.4
- **Change:** +45.4 (+2.54%)
- **Open:** ₹1792
- **Day High:** ₹1848.6
- **Day Low:** ₹1758.1
- **Previous Close:** ₹1790
- **Volume:** 318589
- **As Of:** 2026-09-11T10:22:16+00:00

## Key Fundamentals

Observed at 2026-09-11T04:36:18.480163Z.

- **Market Cap:** ₹29264.48 Cr
- **Classification:** Smallcap
- **P/E (reported):** 102.8
- **P/E (TTM):** 103.75
- **EPS (TTM):** ₹17.69
- **Book Value:** ₹77.86
- **Price to Book:** 23
- **Dividend Yield:** 0.08%
- **ROE:** 19.14%
- **ROCE:** 24.33%
- **Debt to Equity:** 0.24
- **Revenue (yearly):** ₹1761.7 Cr
- **Net Income:** ₹246.7 Cr
- **EBITDA:** ₹408 Cr
- **52-Week High:** ₹1899
- **52-Week Low:** ₹570.75
- **RSI (14):** 56.27

## Tapetide Score

- **Score:** 36 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 7.3 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 56.7 | 9% |
| growth | 98.9 | 9% |
| momentum | 98.2 | 12% |
| ownership | 26.04 | 24% |
| quality | 29.4 | 22% |
| valuation | 15.35 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is expected to give good quarter
- Company has delivered good profit growth of 52.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%

### Weaknesses

- Stock is trading at 23.5 times its book value
- Working capital days have increased from 68.8 days to 104 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 28.82% | 875.96% | 427.4% |
| ebitda margin growth | 11.13% | 11.35% | 16.73% | -442.1% |
| net income growth | 10.42% | 83.56% | 155% | 52% |
| revenue growth | 4.55% | 36.79% | 65% | 41% |
| roce | 9.73% | -30.01% | -2.6% | 14.22% |
| roe | 10.41% | -22.95% | 22.54% | -187.08% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 296 | 313 | 358 | 352 | 412 | 476 | 514 | 534 |
| Expenses | 234 | 244 | 286 | 273 | 318 | 367 | 395 | 405 |
| Operating Profit | 62 | 70 | 72 | 79 | 94 | 108 | 119 | 129 |
| OPM % | 21 | 22 | 20 | 22 | 23 | 23 | 23 | 24 |
| Other Income | 3 | 0 | 0 | 1 | 1 | 4 | 3 | 6 |
| Interest | 7 | 8 | 12 | 11 | 11 | 10 | 10 | 9 |
| Depreciation | 8 | 9 | 10 | 10 | 12 | 12 | 12 | 15 |
| Profit before tax | 49 | 53 | 51 | 60 | 72 | 91 | 99 | 110 |
| Tax % | 30 | 28 | 29 | 27 | 25 | 20 | 22 | 23 |
| Net Profit | 34 | 38 | 36 | 43 | 54 | 73 | 77 | 85 |
| EPS in Rs | 2.27 | 2.5 | 2.35 | 2.81 | 3.49 | 4.42 | 4.65 | 5.13 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 263 | 315 | 314 | 394 | 854 | 1284 | 1754 | 1936 |
| Expenses | 182 | 223 | 353 | 375 | 699 | 1020 | 1354 | 1486 |
| Operating Profit | 81 | 92 | -39 | 18 | 155 | 264 | 400 | 450 |
| OPM % | 31 | 29 | -12 | 4.7 | 18 | 21 | 23 | 23 |
| Other Income | 18 | 10 | 17 | 25 | 18 | 4 | 8 | 13 |
| Interest | 6 | 9 | 10 | 19 | 31 | 37 | 42 | 41 |
| Depreciation | 18 | 29 | 34 | 36 | 39 | 37 | 45 | 51 |
| Profit before tax | 74 | 63 | -66 | -11 | 103 | 195 | 321 | 371 |
| Tax % | 33 | 51 | 2 | 53 | 12 | 31 | 23 | — |
| Net Profit | 49 | 31 | -67 | -17 | 91 | 134 | 247 | 288 |
| EPS in Rs | 97.46 | 60.53 | -132.39 | -33.31 | 5.98 | 8.72 | 14.95 | 17.69 |
| Dividend Payout % | 2 | 2 | 0 | -2 | 0 | 0 | 10 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 5 | 5 | 5 | 5 | 15 | 15 | 17 |
| Reserves | 335 | 369 | 300 | 281 | 370 | 526 | 1272 |
| Borrowings | 30 | 93 | 175 | 320 | 425 | 418 | 311 |
| Other Liabilities | 60 | 71 | 79 | 144 | 300 | 493 | 727 |
| Total Liabilities | 430 | 538 | 560 | 750 | 1109 | 1451 | 2327 |
| Fixed Assets | 157 | 188 | 193 | 199 | 307 | 327 | 532 |
| CWIP | 2 | 6 | 3 | 25 | 10 | 7 | 41 |
| Investments | 19 | 14 | 0 | 0 | 0 | 0 | 27 |
| Other Assets | 252 | 330 | 364 | 526 | 793 | 1118 | 1728 |
| Total Assets | 430 | 538 | 560 | 750 | 1109 | 1451 | 2327 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 5 | 62 | -63 | -75 | 21 | 159 | 205 |
| Cash from Investing Activity | -84 | -46 | -46 | -32 | -68 | -65 | -407 |
| Cash from Financing Activity | 80 | 52 | 63 | 123 | 44 | -40 | 283 |
| Net Cash Flow | 1 | 67 | -45 | 16 | -4 | 54 | 81 |
| Free Cash Flow | -54 | -10 | -117 | -119 | -35 | 91 | -24 |
| CFO/OP | 40 | 104 | 138 | -394 | 25 | 75 | 78 |

### Ratios

| Item | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 194 | 158 | 162 | 209 | 129 | 92 | 106 |
| Inventory Days | 360 | 508 | 502 | 609 | 428 | 574 | 550 |
| Days Payable | 183 | 271 | 320 | 353 | 252 | 263 | 285 |
| Cash Conversion Cycle | 371 | 395 | 345 | 465 | 305 | 403 | 371 |
| Working Capital Days | 183 | 149 | 107 | 75 | 57 | 46 | 104 |
| ROCE % | — | 17 | -12 | 1 | 19 | 26 | 28 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- |
| Promoters | 59.99% | 59.99% | 59.86% | 59.76% |
| FIIs | 9.37% | 7.99% | 7.54% | 7.52% |
| DIIs | 10.54% | 9.45% | 10.02% | 9.43% |
| Government | 0% | 0% | 0% | 0% |
| Public | 18.28% | 2.71% | 2.82% | 3.46% |
| Others | 1.82% | 19.86% | 19.76% | 19.84% |
| No. of Shareholders | 105311 | 31914 | 33738 | 43254 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 6 / 1

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 1805.95 | Buy |
| EMA (10) | 1802.32 | Buy |
| SMA (20) | 1794.78 | Buy |
| EMA (20) | 1766.95 | Buy |
| SMA (50) | 1621.51 | Buy |
| EMA (50) | 1628.03 | Buy |
| SMA (100) | 1376.59 | Buy |
| EMA (100) | 1425.21 | Buy |
| SMA (200) | 1051.58 | Buy |
| EMA (200) | 1100.37 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 59.95 | Neutral |
| MACD (12,26,9) | 56.49 | Sell |
| Stochastic (14,3,3) | 57.29 | Neutral |
| ADX (14) | 29.43 | Buy |
| Williams %R (14) | -31.21 | Neutral |
| ATR (14) | 74.96 | High Volatility |
| ROC (12) | 0.91 | Buy |
| Stoch RSI (14) | 37.98 | Neutral |
| UO (7,14,28) | 51.58 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 2 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 2 analyst ratings, observed at 2026-09-11T04:36:15.542016+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-29 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=A21451F0_EF4E_4E4A_8F61_EEEFD1EA201F_111427.pdf) |
| 2026-08-27 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=BBEA150D_0A6A_48E4_971B_042A109DE82E_091853.pdf) |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d60e8ad3-af49-4bb7-8924-e9c9c39fdd07.pdf) |
| 2026-08-26 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=28587f02-884a-4812-9955-aa8b460a9b3d.pdf) |
| 2026-08-15 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ec4fe6c0-8afe-44e1-9269-0564e77a5177.pdf) |
| 2026-08-14 | [Board Meeting Outcome for Unaudited Financials Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5496d111-9826-4ced-bfcc-ef52a5f807f6.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0ed42b8b-a41b-4be6-a3a7-ae3aa0f7a140.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Monitoring Agency Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5a75e15d-ec45-45e0-a15d-2d484ceebaa1.pdf) |
| 2026-08-13 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=db9691e7-82f3-4cfb-861d-aecf6c53f369.pdf) |
| 2026-08-11 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1f35af51-369d-4bd8-9e04-71bc2c7af49b.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=453a6033-2181-4329-a173-3ecd5b151f84.pdf) |
| 2026-06-02 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a3171339-dcbb-4cd8-be1c-4d77c06e9073.pdf) |
| 2026-02-06 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc12dcf3-bea3-4afc-9672-5caecc459739.pdf) |
| 2025-11-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bc7cf3c3-82d9-4d1f-84b3-908b46eb40e3.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=31af2488-2e29-4ee1-8551-07ea34a51255.pdf) |
| 2026-05-29 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fd7eafe8-21e2-456b-abb1-e562008f65e1.pdf) |
| 2026-02-03 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=bb38d485-1743-4c3e-b8f1-f32a24b1dd45.pdf) |
| 2025-11-13 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=07a97ce1-1340-46b8-95bd-92f0092cc909.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-14 | [Audio Recording Of Earnings Conference Call For The Quarter Ended 30Th June 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1cc1e4a7-0192-4c5d-82b8-074910d97184.pdf) |
| 2026-05-30 | [Earnings Call Audio Recording](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7504a26a-a416-4204-8ab4-2847f2b81020.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bc7cf3c3-82d9-4d1f-84b3-908b46eb40e3.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fd7eafe8-21e2-456b-abb1-e562008f65e1.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/fd7eafe8-21e2-456b-abb1-e562008f65e1.pdf) |
| Jun 2026 | [Concall - Jun 2026](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a3171339-dcbb-4cd8-be1c-4d77c06e9073.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-05-29 | [Audited Financial Results For The Quarter And Year Ended 31 March 2026 And Recommendation Of Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d486096c-789a-427c-842b-cc71fd20d349.pdf) |
| 2026-02-03 | [Results - Financial Results For 31-12-2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a47250ed-a669-46f3-bfb0-649d265e3673.pdf) |
| 2025-11-13 | [Results-Financial Results For 30-09-2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77374620-e261-4141-b8fa-339b6c83dfe8.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 5h - USFDA inspection of Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Outcome Of USFDA Inspection At The Company'S R&D Facility In Canada 5h - USFDA inspection of Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/09c9dc0d-d325-4ad8-bf2a-779d48a220ac.pdf) |
| 5h - USFDA inspection at Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Outcome Of USFDA Inspection At The Company'S R&D Facility In Canada 5h - USFDA inspection at Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/f763cb9f-5e20-45e8-b000-441a0dce1e1c.pdf) |
| 31 Mar - Allotment of Equity shares pursuant to exercise of ESOPs | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS 31 Mar - Allotment of Equity shares pursuant to exercise of ESOPs](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5a3e8822-0147-4723-be64-610598e3d819.pdf) |
| 30 Apr - Rubicon completed 85% secondary acquisition of Arinna Lifesciences on April 30, 2026; Arinna becomes subsidiary. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations') - Completion Of Acquisition Of Securities In Arinna Lifesciences Limited 30 Apr - Rubicon completed 85% secondary acquisition of Arinna Lifesciences on April 30, 2026; Arinna becomes subsidiary.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2b2e15a2-9f01-4491-8df8-f3759a6e71c8.pdf) |
| 30 Apr - Rubicon completed 85% secondary acquisition of Arinna Lifesciences on April 30, 2026; Arinna becomes subsidiary. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 ('SEBI Listing Regulations') - Completion Of Acquisition Of Securities In Arinna Lifesciences Limited 30 Apr - Rubicon completed 85% secondary acquisition of Arinna Lifesciences on April 30, 2026; Arinna becomes subsidiary.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2b2e15a2-9f01-4491-8df8-f3759a6e71c8.pdf) |
| 3 Feb - Feb 3, 2026: Dr Pradnya appointed; Anand Agarwal resigned; in‑principle merger of KIA (Net worth Rs.815.80L). | [General Updates 3 Feb - Feb 3, 2026: Dr Pradnya appointed; Anand Agarwal resigned; in‑principle merger of KIA (Net worth Rs.815.80L).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/914eb951-cc53-425a-ada7-e40c7a6c3225.pdf) |
| 27 Apr - Rubicon Research says it is not a Large Corporate under SEBI debt fundraising rules; outstanding borrowing Rs 40.17 crore. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 27 Apr - Rubicon Research says it is not a Large Corporate under SEBI debt fundraising rules; outstanding borrowing Rs 40.17 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cb872ddf-e2d6-443d-b9c1-9236df0d040a.pdf) |
| 24 Apr - USFDA inspection of Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Outcome Of USFDA Inspection At The Company'S R&D Facility In Canada 24 Apr - USFDA inspection of Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/09c9dc0d-d325-4ad8-bf2a-779d48a220ac.pdf) |
| 24 Apr - USFDA inspection at Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued. | [Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015 - Outcome Of USFDA Inspection At The Company'S R&D Facility In Canada 24 Apr - USFDA inspection at Concord, Ontario R&D facility ended April 24, 2026 with no Form-483 issued.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f763cb9f-5e20-45e8-b000-441a0dce1e1c.pdf) |
| 22 Apr - Income tax assessment for AY 2023-24 raises Rs. 17.25 crore demand; appeal planned. | [Intimation Under Regulation 30 Read With Schedule III Of The SEBI (LODR) Regulations, 2015 (Listing Regulations) 22 Apr - Income tax assessment for AY 2023-24 raises Rs. 17.25 crore demand; appeal planned.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9b26e2f4-0642-435e-997d-7bc297104899.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/AR_30163_RUBICON_2025_2026_A_17300952_03082026214807.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:26:33.048Z.